Scarica l'app Stockscreener
5.25
1.50%
-0.08
Dopo l'orario di chiusura:
5.48
0.23
+4.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now? - MSN
Myriad Genetics at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com Canada
Transcript : Myriad Genetics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Consumer Genomics Market Is Booming So Rapidly 2025-2032 | Color - openPR.com
5-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
3 Reasons to Avoid MYGN and 1 Stock to Buy Instead - FinancialContent
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen - GlobeNewswire
7-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline is Approaching - ACCESS Newswire
FINAL DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Myriad Genetics (MYGN) Investors Who Suffered Significant Losses to Contact Its Attorneys, Application Deadline Tomorrow - ACCESS Newswire
Trend Tracker for (MYGN) - news.stocktradersdaily.com
US Direct-To-Consumer Genetic Testing Market Report 2025, - GlobeNewswire
US Direct-To-Consumer Genetic Testing Market Report 2025, Competitive Analysis of 23andMe, Gene by Gene, Ancestry, Genesis, EasyDNA, Veritas, Myriad Genetics, Taconic Biosciences, & Color Health - Yahoo Finance
Myriad Genetics (MYGN) Launches FirstGene Multiple Prenatal Screen | MYGN Stock News - GuruFocus
Myriad Genetics Launches FirstGene™ Prenatal Screen for Comprehensive Genetic Risk Assessment in One Blood Draw - Nasdaq
Breakthrough Prenatal Screen Combines 4 Tests in 1 Blood DrawNo Father Sample Needed - Stock Titan
Hereditary Testing MarketGlobal Industry Trends, - GlobeNewswire
MYGN INVESTOR REMINDER: Hagens Berman Reminds Myriad Genetics (MYGN) Investors of Securities Fraud Lawsuit, Encourages Investors Who Lost $50,000+ to Contact the Firm - ACCESS Newswire
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - GlobeNewswire
Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study - Nasdaq
Myriad Genetics (MYGN) Reports Promising Results from MONSTAR-SCREEN 3 Study | MYGN Stock News - GuruFocus
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types - GlobeNewswire
Breakthrough: Myriad Genetics New Cancer Test Detects Tumors 60% Better Than First-Gen Tests - Stock Titan
Ameriprise Financial Inc. Has $2.88 Million Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025 - Insider Monkey
Myriad Genetics Highlights New Research Advancements and Oncolog - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting | MYGN Stock News - GuruFocus
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting - GlobeNewswire
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Man Group plc Makes New $390,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Revolutionary Cancer Detection: Myriad Genetics' New Test Shows Perfect Accuracy in Major Clinical Trial - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Deutsche Bank AG Purchases 27,541 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Hereditary Cancer Testing Market Size | Industry Report 2030 - Grand View Research
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud - ACCESS Newswire
Trading (MYGN) With Integrated Risk Controls - news.stocktradersdaily.com
ATTENTION MYGN Shareholders: Lost Money on Myriad Genetics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Scotiabank Downgrades Myriad Genetics (NASDAQ:MYGN) to Sector Perform - Defense World
Microtomes Market Generated Opportunities, Future Scope - openPR.com
Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com
BNP Paribas Financial Markets Purchases 23,408 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Captrust Financial Advisors Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Myriad Genetics Shares Fall After Downgrade From Scotiabank - marketscreener.com
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Genetic Counseling Market Deep Research Report with Forecast by 2032 | Invitae Corporation, Myriad Genetics - openPR.com
Myriad Genetics (MYGN) Faces Downgrade and Price Target Reduction | MYGN Stock News - GuruFocus
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Scotiabank Downgrades Myriad Genetics (MYGN) With Revised Price - GuruFocus
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
0.43%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):